Study to Evaluate CAY001 in Healthy Volunteers

Phase 1 Recruiting 24 enrolled Cayuga Biotech, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CAY001 when administered to healthy male and female subjects. Three dose levels will be evaluated with a total of approximately 24 subjects.

Timeline

Start: 2025-12-02
Primary completion: 2026-10-30
Completion: 2026-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAY001	Unknown	—	Intravenous

Indications

No indication recorded.